Nivolumab vs investigator ’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Squamous cell carcinoma of the head and neck (SCCHN) includes neoplasms in the oral cavity, pharynx, and larynx, and accounts for 90% of all head and neck cancers [1 –3]. Patients with recurrent/metastatic (R/M) SCCHN who progress within 6 months after platinum-based therapy have poor long-term prognosis and limited treatment options, with a median overall survival (OS) of ≤6 months [4,5]. In 2016, nivolumab was approved in the United States for the trea tment of this patient population, with European approval following in 2017 [6,7].

Source: Oral Oncology - April 17, 2018 Category: Cancer & Oncology Authors: Robert L. Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Source Type: research